BioSpace News Archive

The Monoclonal Antibodies market was estimated at US$ 95.4 billion in 2020 and is expected to hit around US$ 150.4 billion by 2030, growing at a CAGR of 15.7% from 2021 to 2030.

The global Ophthalmic Ultrasound Devices market size is predicted to hit around US$ 887.7 million by 2030 from valued at US$ 487.50 million in 2020 and growing at a CAGR of 9.36% during forecast period 2021 to 2030.

The global Orthopedic Soft Tissue Repair market size is expected to be worth around US$ 19.39 billion by 2030 from valued at US$ 15.0 billion in 2020 with a CAGR of 6.5% from 2021 to 2030.

The global RNA Analysis market size is expected to hit around US$ 30.48 billion by 2030 and is projected to grow at a CAGR of 14.44% during forecast period 2021 to 2030.

The global sinusitis treatment market was estimated at US$ 3 bn in 2020 and is expected to hit US$ 4.3 billion by 2030 with at a CAGR of 4.1% from 2021 to 2030.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present four posters on its Multi-Tumor-Associated Antigen (MultiTAA)-specific T cell therapies at the 2022 International Society for Cell & Gene Therapy (ISCT) Annual Meeting.

The global Asthma Drugs Market was valued at USD 20.6 Billion in 2020 and is estimated to hit USD 36.9 Billion by 2027 with a CAGR of 5.0% during the forecast period 2021 to 2027.

The global stem cells market was estimated at USD 12.53 billion in 2021 and it is projected to hit around USD 29.68 billion by 2030 poised to grow at a CAGR of 12.4% from 2022 to 2030.

Sarepta Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 9:20 a.m. P.T. / 12:20 p.m. E.T.

Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women with early-stage breast cancer.